One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per trial, a newly completed study by the Tufts Center for the Study of Drug Development has found.
According to Tufts CSDD, 18 percent of a typical clinical trial budget, or $1.1 million, is spent on direct costs to administer procedures for supplementary secondary, tertiary, and exploratory endpoints.
"The impetus to collect these data is strong, and until now there has been no systematic assessment of this practice," said Ken Getz, assistant professor at Tufts CSDD. "We believe our findings offer a framework that pharmaceutical and biotechnology companies can use to streamline protocol designs, improve clinical research performance, and reduce development costs."
Based on the total number of active Phase 2 and 3 clinical trials regulated by the U.S. Food and Drug Administration, Tufts CSDD conservatively estimates that the pharmaceutical industry spends between $4 billion and $6 billion each year on procedures that generate extraneous clinical trial data.
The study, reported in the November/December Tufts CSDD Impact Report, released today, also found that:
• An average 22.3% of all clinical trial procedures are considered to be non-core, including 17.7% of Phase 2 procedures and 24.7% of Phase 3 procedures.
• Half of all procedures-54.3% of Phase 2 procedures and 47.9% of Phase 3-support primary and key secondary endpoints.
• The typical clinical trial protocol has an average of 13 endpoints, with the number of less essential endpoints per protocol nearly doubling the average level observed 10 years ago.
Date: November 6, 2012
Source: Tufts Center for the Study of Drug Development